RECORD // Company

First Tracks Biotherapeutics, Inc.

Formerly: Biopharma Company, Inc.

Built 2026-11-22T00:12:03Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • FIRST TRACKS BIOTHERAPEUTICS INC · Ca business · same registered legal name as 'First Tracks Biotherapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • FIRST TRACKS BIOTHERAPEUTICS INC · Epa echo · same registered legal name as 'First Tracks Biotherapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-03 · accession 0001193125-26-445430

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-31,356,0003 months ended 2026-09-3010-Q2026-11-030001193125-26-4454302026-11-22 00:12 UTCReport an error
Cash and cash equivalents$155,627,000at 2026-09-3010-Q2026-11-030001193125-26-4454302026-11-22 00:12 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0002091349
Ticker
TRAX
EIN
395003207
CUSIP
337185102
Record ID
sx:sec:0002091349

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

23 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-12SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-12SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
State of incorporationDE2026-11-12SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
Fiscal year end (MMDD)12312026-11-12SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
Business address10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 921212026-11-12SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
ExchangesNasdaq2026-11-12SEC EDGAR company profile2026-11-22 00:12 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-03)On November 3, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall…2026-11-03SEC EDGAR 8-K 0001193125-26-445405 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-20)On October 19, 2026 (the “Closing Date”), First Tracks Biotherapeutics, Inc. (the “Company”) closed its previously announced private placement (the “Private Placement”) of an aggregate 6,106,870 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share. At the closing of the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the investors in the Private Placement (the “Investors”). Pursuant to the Registration Rights Agreement, the Company is required to file or confidentially submit a registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale by the Investors of…2026-10-20SEC EDGAR 8-K 0001193125-26-426666 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-15)On October 15, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks Biotherapeutics” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain third party investors (collectively, the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate 6,106,870 shares of the Company’s common stock (the “Common Stock”), par value $0.001 per share (the “Offered Securities”) to the Investors, at a purchase price of $32.75 per share (the “Private Placement”). The aggregate gross proceeds to First Tracks Biotherapeutics from the sale of the Offered Securities is expected to be approximately $200 million, before deducting placement…2026-10-15SEC EDGAR 8-K 0001193125-26-422929 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-10-15)The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The Offered Securities to be issued in connection with the Purchase Agreement will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and will be issued in reliance on exemptions from registration requirements thereof, including exemptions provided by Section 4(a)(2) of the Securities Act. As of October 12, 2026, the Company had 35,909,814 shares of Common Stock issued and outstanding.2026-10-15SEC EDGAR 8-K 0001193125-26-422929 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-15)On October 15, 2026, the Company issued a press release announcing the Private Placement, a copy of which is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information furnished in Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Forward-Looking…2026-10-15SEC EDGAR 8-K 0001193125-26-422929 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-13)On October 12, 2026, First Tracks Biotherapeutics, Inc. (the “Company”) updated its corporate investor presentation, a full copy of which is attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.2026-10-13SEC EDGAR 8-K 0001193125-26-419761 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-13)On October 12 2026, the Company issued a press release announcing positive topline data from the first Phase 1b cohort of ANB033 in Celiac Disease. A copy of the press release is filed herewith as Exhibit 99.2.2026-10-13SEC EDGAR 8-K 0001193125-26-419761 (text as filed, excerpt)2026-11-22 00:12 UTCReport an error
Largest institutional holder #1 (13F as filed): EcoR1 Capital, LLC$63,871,3222026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #2 (13F as filed): TCG Crossover Management, LLC$58,253,5162026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #3 (13F as filed): FMR LLC$41,329,0452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #4 (13F as filed): Affinity Asset Advisors, LLC$40,884,0812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #5 (13F as filed): BlackRock, Inc.$39,506,4462026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #6 (13F as filed): Trails Edge Capital Partners, LP$30,461,6802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$29,212,4092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #8 (13F as filed): Jupiter Topco LLC$21,960,3682026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #9 (13F as filed): Vestal Point Capital, LP$20,381,5602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error
Largest institutional holder #10 (13F as filed): Woodline Partners LP$18,453,5812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:12 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.